Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries

Navidea Biopharmaceuticals Inc (NY: NAVB )

N/A UNCHANGED
Last Price Updated: 8:00 PM EDT, Oct 5, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Navidea Biopharmaceuticals Inc

< Previous 1 2 3 4 5 6 Next >
The Week Ahead In Biotech (March 20-26): Focus On Zogenix FDA Decision, Dermatology Conference Presentations & Earnings
Biotech stocks rebounded along with the broader market in the week ending March 18, as risk appetite returned. Multiple conference presentations, clinical readouts and earnings news dictated sentiment... 
Via Benzinga
Navidea Biopharmaceuticals to Host Fourth Quarter 2021 Earnings Conference Call and Business Update
From Navidea Biopharmaceuticals, Inc.
Via Business Wire
Navidea Shares Jump On Research Pact For Tc99m Tilmanocept As Biomarker In Brain Cancer
Navidea Biopharmaceuticals Inc (NYSE: NAVB) has  
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
On Friday, 209 companies set new 52-week lows. Interesting Facts About Today's 52-Week Lows: Meta Platforms (NASDAQ:FB) was the largest firm on a market cap... 
Via Benzinga
47 Biggest Movers From Yesterday
Gainers Nuvectis Pharma, Inc. (NASDAQ: NVCT) shares surged 144.6% to close at $7.95 on Monday. The company, on Friday, priced its IPO at $5 per share. Anghami Inc. (NASDAQ: ANGH... 
Via Benzinga
Navidea Biopharmaceuticals Announces Research Agreement with the University of Pennsylvania Evaluating Tc99m Tilmanocept as a Prognostic Marker for Glioblastoma
From Navidea Biopharmaceuticals, Inc.
Via Business Wire
Navidea Biopharmaceuticals Announces Settlement of Platinum Litigation; Receipt of Noncompliance Notice from NYSE American
From Navidea Biopharmaceuticals, Inc.
Via Business Wire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Good morning, trader! It's time to kick off another day with a dive into the biggest pre-market stock movers for Tuesday! 
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
We've reached the halfway point of the week and we're starting it with an overview of the biggest pre-market stock movers for Wednesday! 
Via InvestorPlace
The Daily Biotech Pulse: Genfit Spikes On Liver Disease Drug Licensing Deal, Lyell Gets Nod For Solid Tumor Study, Decision-Day For Intra-Cellular, Argenx
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Merck Announces Publication Of Positive Data From Late-Stage Study Of Oral... 
Via Benzinga
Navidea Biopharmaceuticals Announces Launch of Phase 3 Clinical Trial in Rheumatoid Arthritis
From Navidea Biopharmaceuticals, Inc.
Via Business Wire
Navidea Shares Gain After Terminating Stock Purchase Agreement
Navidea Biopharmaceuticals Inc (NYSE: NAVB) has terminated the Stock Purchase Agreement executed on August 30, 2020. The investors agreed to purchase up to $25.0... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Good morning, trader! We're getting right into the swing of things with a breakdown of the biggest pre-market stock movers for Thursday! 
Via InvestorPlace
18 Stocks Moving in Thursday's Pre-Market Session
Gainers Calliditas Therapeutics AB (NASDAQ: CALT) rose 36.5% to $25.45 in pre-market trading after the company announced it was granted by the FDA accelerated approval of TARPEYO... 
Via Benzinga
Navidea Biopharmaceuticals Completes Full Enrollment in Phase 2b Normative Database Study to Support its Rheumatoid Arthritis Program
From Navidea Biopharmaceuticals, Inc.
Via Business Wire
Navidea Biopharmaceuticals Terminates Stock Purchase Agreement
From Navidea Biopharmaceuticals, Inc.
Via Business Wire
Navidea Biopharmaceuticals Announces Third-Party Asset Valuation of Tc99m Tilmanocept for Indications in Rheumatoid Arthritis
From Navidea Biopharmaceuticals, Inc.
Via Business Wire
Navidea Biopharmaceuticals Announces Business Update Call and Changes to Board of Directors Composition
From Navidea Biopharmaceuticals, Inc.
Via Business Wire
Navidea Biopharmaceuticals Reports Third Quarter 2021 Financial Results
From Navidea Biopharmaceuticals, Inc.
Via Business Wire
Wall Street Crime and Punishment: Martin Shkreli, The Self-Destructive Pharma Bro
Does crime pay? Wall Street Crime and Punishment is a weekly series by Benzinga's Phil Hall chronicling the bankers, brokers and financial ne’er-do-wells whose ambition... 
Via Benzinga
Navidea Biopharmaceuticals to Host Third Quarter 2021 Earnings Conference Call and Business Update
From Navidea Biopharmaceuticals, Inc.
Via Business Wire
The Daily Biotech Pulse: Valneva Inks COVID-19 Vaccine Supply Contract In Europe, I-Mab Spikes On China Deal, DermTech Sinks On Guidance
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus MorphoSys COO To Leave To Pursue Other Opportunities MorphoSys AG (NASDAQ:... 
Via Benzinga
Exposures COVID-19
Navidea Biopharmaceuticals Announces Resignation of Jed A. Latkin
From Navidea Biopharmaceuticals, Inc.
Via Business Wire
Navidea Biopharmaceuticals Appoints Thomas Forest Farb-Horch and Agnieszka Winkler to the Board of Directors
From Navidea Biopharmaceuticals, Inc.
Via Business Wire
Looking Into Navidea Biopharmaceutical's Return On Capital Employed
According to Benzinga Pro data, during Q2, Navidea Biopharmaceutical (AMEX:NAVB) posted sales of $261.05 thousand. Earnings were up 19.83%, but Navidea Biopharmaceutical still... 
Via Benzinga
Navidea Biopharmaceuticals Appoints Michel Mikhail, Ph.D. as Chief Regulatory Officer
From Navidea Biopharmaceuticals, Inc.
Via Business Wire
4 Penny Stocks Insiders Are Buying
When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider... 
Via Benzinga
Navidea Biopharmaceuticals Announces Changes to Board of Directors Composition
From Navidea Biopharmaceuticals, Inc.
Via Business Wire
Navidea Biopharmaceuticals Reports Second Quarter 2021 Financial Results
From Navidea Biopharmaceuticals, Inc.
Via Business Wire
The Daily Biotech Pulse: FDA Rejects FibroGen's Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 10) Alnylam Pharmaceuticals,... 
Via Benzinga
Exposures Product Safety
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.